You are here

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
11. Translational Research/Biomarkers
#836 Liquid biopsy isolation of circulating tumour cells from epithelial ovarian cancer patients and their prognostic significance
Free
  1. Mark P Ward1,
  2. Faye Lewis1,
  3. Catherine O’Gorman2,
  4. Tanya E Kelly1,
  5. Bashir M Mohamed1,
  6. Brian Henderson1,
  7. Sined Hurley1,
  8. Roisin O’Connor1,
  9. Robert D Brooks3,
  10. Doug A Brooks3,
  11. Stavros Selemidis4,
  12. Patrick Maguire2,
  13. Waseem Kamran2,
  14. James P Beirne2,
  15. Feras A Saadeh2,
  16. Karen Cadoo5,
  17. Lucy A Norris6,
  18. Cara Martin1,
  19. Sharon A O’Toole1 and
  20. John J O’Leary1
  1. 1Department of Histopathology, Trinity College Dublin, Dublin, Ireland
  2. 2Division of Gynaecological Oncology, St James’s Hospital, Dublin, Ireland
  3. 3Cancer Research Institute, University of South Australia, Adelaide, Australia
  4. 4School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia
  5. 5The Haematology, Oncology and Palliative Care (HOPe) Directorate, St James’s Hospital, Dublin, Ireland
  6. 6Department of Obstetrics and Gynaecology, Trinity College Dublin, Dublin, Ireland

Abstract

Introduction/Background Cancer cells that transit from primary tumours into the blood circulatory system are known as circulating tumour cells (CTCs). Research has highlighted the difficulties with detection of CTCs from ovarian cancer patients using EpCAM-based techniques, with classical EpCAM-CTC enumeration alone having limited prognostic significance. This study aims to isolate epithelial ovarian CTCs from patients using ANGLE-Parsortix technology.

Methodology Peripheral blood specimens [n=106] were prospectively collected from 54 newly diagnosed epithelial ovarian cancer patients since November 2020. Samples were taken pre and post-neoadjuvant chemotherapy, pre-surgery and during cytoreduction surgery from the central ovarian vein. Longitudinal sampling is ongoing. CTCs were isolated using Parsortix microfluidic device and immunophenotyped (CTC-ID; DAPI, CD45, CK7/panCK/EpCAM] by immunofluorescence and confocal microscopy.

Results 66% of patients recruited had at least 1 CTC detected [CTC range of 1–22 cells per 7.5 ml of blood]. CTCs were present in 74% of ovarian vein [n=19] samples [CTC range of 1–2475 cells]. Patients with ≥2 CTCs had higher CA125 levels. Median PFS was significantly lower at 13.5 months in patients with ≥2 CTCs compared to 21 months with <2 CTCs. No statistical difference was seen between pre and post neoadjuvant CTC counts, however, a number of poor chemotherapy responders had persistent CTC levels following treatment. CTC clusters were significantly isolated from the ovarian vein. Follow up of treatment response, PFS, overall survival and 1 year blood-sampling follow up is currently ongoing to establish the clinical significance of single CTCs and CTC clusters detection in the primary surgery and neoadjuvant setting.

Conclusion We report that using ANGLE-Parsortix CTC enrichment, single CTCs and CTC clusters can be isolated from blood in ovarian cancer. CTCs isolated from the ovarian vein during surgery are abundant for the precursor metastasising cells that are CTC-clusters, and may show utility for monitoring treatment response and prognosis in the adjuvant setting.

Disclosures No authors have any potential conflict of interest to report.

https://doi.org/10.1136/ijgc-2023-ESGO.784

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.